Entering text into the input field will update the search result below

Dosing underway in early-stage studies of Celyad's CAR-T therapy CYAD-01

May 03, 2018 9:17 AM ETCelyad Oncology SA (CYADY) StockBy: Douglas W. House, SA News Editor
  • Celyad (NASDAQ:CYAD) announces that the first patients have been treated with lead candidate CYAD-01 in two early-stage studies and both appear to be tolerating the CAR-T therapy well.
  • One study, SHRINK, is assessing multiple doses of CYAD-01, in combination with the chemo regimen FOLFOX, in patients with colorectal cancer (CRC) with possibly resectable liver metastases. Primary objectives are safety, specifically dose-limiting toxicities, and objective response rate. According to ClinicalTrials.gov, the estimated completion date is May 2021.
  • The other, LINK, is assessing CYAD-01 in CRC patients with unresectable liver metastases. Its estimated completion date is July 2020. The primary endpoint is safety.
  • Another study, EPITHINK, in AML patients should launch soon.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
CYADY--
Celyad Oncology SA